Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Current Liabilities (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Total Current Liabilities for 6 consecutive years, with $25.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 17.09% to $25.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.4 million through Dec 2025, down 17.09% year-over-year, with the annual reading at $25.4 million for FY2025, 17.09% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $25.4 million at Caribou Biosciences, down from $28.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $34.4 million in Q2 2023, with the low at $24.6 million in Q3 2023.
  • Average Total Current Liabilities over 5 years is $28.3 million, with a median of $28.3 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities soared 108.48% in 2021, then decreased 17.09% in 2025.
  • Over 5 years, Total Current Liabilities stood at $25.8 million in 2021, then rose by 8.9% to $28.1 million in 2022, then rose by 0.62% to $28.3 million in 2023, then grew by 8.3% to $30.7 million in 2024, then fell by 17.09% to $25.4 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $25.4 million, $28.1 million, and $28.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.